Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q3 2024 (September 30)16holders +5
5new positions
0sold out
$1.03avg. 13F price*
At the end of Q3 2024, 16 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, up 5 from Q2 2024. 5 opened new positions and 0 sold out. The largest holders were Sonora Investment Management Group, LLC ($4.1M), New York State Common Retirement Fund ($3.4M) and Toronto Dominion Bank ($3.0M).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $3.9M |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 3,752,389 shares bought and 105,000 shares sold, net +3,647,389 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Sonora Investment Management Group, LLC | 0.31% | Reduce -2.5% | 4,117,000 | $4.1M |
| New York State Common Retirement Fund | 0.00% | New | 3,442,000 | $3.4M |
| Toronto Dominion Bank | 0.01% | No change | 3,000,000 | $3.0M |
| Bank of New York Mellon Corp | 0.00% | Add +16.7% | 700,000 | $702K |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 650,000 | $650K |
| Nomura Holdings Inc. | 0.00% | New | 5,830 | $334K |
| Cetera Investment Advisers | 0.00% | No change | 193,000 | $193K |
| &partners | 0.00% | Add +76.5% | 143,000 | $143K |
| Cerity Partners LLC | 0.00% | Add +0.1% | 43,043 | $86K |
| Rollins Financial Advisors, LLC | 0.01% | New | 54,000 | $54K |
| Mariner, LLC | 0.00% | New | 54,000 | $54K |
| Choreo, LLC | 0.00% | Add +67.9% | 47,000 | $47K |
| Lanark Financial, Inc. | 0.00% | No change | 13,000 | $13K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | Add +78.6% | 12,500 | $13K |
| Comerica Bank | 0.00% | New | 10,000 | $10K |
| Laffer Tengler Investments, Inc. | 0.00% | Add +0.8% | 1,982 | $2K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.